I get what you're saying, but given all of those things, do you think BP could really come up with a BO price that would be acceptable? I think we would all want a hefty cash price ($25-50/share minimum) and also stock in the acquiring company, because leronlimab is going to be the proverbial gift that keeps on giving and we are all going to want to be a part of that, as will NP and his board.

Granted, CYDY is barely a company, with what, 7 employees or so? They clearly have to outsource everything, so while it would appear that a partnership or BO is a must, again, I just wonder if the money for a BO is really possible given the financial potential here.

What do you see as financially acceptable for a BO if we do get BTD for breast cancer, the basket trial, and approval for combo HIV (knowing that approval for mono wouldn't be far off either)? This of course doesn't even touch on BTD for GvHD and also a NASH partnership which NP mentioned within a year. The Vyera deal could hamstring us a bit too...